Literature DB >> 27012190

The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Robert J Kurman1, Ie-Ming Shih2.   

Abstract

Since our proposal of a dualistic model of epithelial ovarian carcinogenesis more than a decade ago, a large number of molecular and histopathologic studies were published that have provided important insights into the origin and molecular pathogenesis of this disease. This has required that the original model be revised and expanded to incorporate these findings. The new model divides type I tumors into three groups: i) endometriosis-related tumors that include endometrioid, clear cell, and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and malignant Brenner tumors. As in the previous model, type II tumors are composed, for the most part, of high-grade serous carcinomas that can be further subdivided into morphologic and molecular subtypes. Type I tumors develop from benign extraovarian lesions that implant on the ovary and which can subsequently undergo malignant transformation, whereas many type II carcinomas develop from intraepithelial carcinomas in the fallopian tube and, as a result, disseminate as carcinomas that involve the ovary and extraovarian sites, which probably accounts for their clinically aggressive behavior. The new molecular genetic data, especially those derived from next-generation sequencing, further underline the heterogeneity of ovarian cancer and identify actionable mutations. The dualistic model highlights these differences between type I and type II tumors which, it can be argued, describe entirely different groups of diseases.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27012190      PMCID: PMC5808151          DOI: 10.1016/j.ajpath.2015.11.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  101 in total

1.  Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.

Authors:  Russell Vang; Allen M Gown; Todd S Barry; Darren T Wheeler; Brigitte M Ronnett
Journal:  Int J Gynecol Pathol       Date:  2006-01       Impact factor: 2.762

2.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

3.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Authors:  Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

4.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

5.  Loss of p16INK4A expression in low-grade ovarian serous carcinomas.

Authors:  Peter W Schlosshauer; Liane Deligdisch; Frédérique Penault-Llorca; Delaram Fatemi; Rui Qiao; Shen Yao; Meghan Pearl; Zhen Yang; Tao Sheng; Jianli Dong
Journal:  Int J Gynecol Pathol       Date:  2011-01       Impact factor: 2.762

6.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

7.  Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.

Authors:  Joshy George; Kathryn Alsop; Dariush Etemadmoghadam; Heather Hondow; Thomas Mikeska; Alexander Dobrovic; Anna deFazio; Gordon K Smyth; Douglas A Levine; Gillian Mitchell; David D Bowtell
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

8.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

9.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

10.  beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.

Authors:  M Saegusa; M Hashimura; T Yoshida; I Okayasu
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  257 in total

1.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

Review 2.  SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.

Authors:  Takeshi Fukumoto; Elizabeth Magno; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

3.  Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Authors:  Stefani N Thomas; Lijun Chen; Yang Liu; Naseruddin Höti; Hui Zhang
Journal:  J Proteome Res       Date:  2017-09-14       Impact factor: 4.466

4.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

Review 5.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

6.  Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.

Authors:  Friederike Hoellen; Athina Kostara; Thomas Karn; Uwe Holtrich; Ahmed El-Balat; Mike Otto; Achim Rody; Lars C Hanker
Journal:  Mol Clin Oncol       Date:  2016-08-17

7.  NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype.

Authors:  Bing Xin; Kai-Qiang Ji; Yi-Si Liu; Xiao-Dong Zhao
Journal:  Reprod Sci       Date:  2020-10-30       Impact factor: 3.060

8.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

10.  In Utero Exposure to Benzo[a]pyrene Induces Ovarian Mutations at Doses That Deplete Ovarian Follicles in Mice.

Authors:  Ulrike Luderer; Matthew J Meier; Gregory W Lawson; Marc A Beal; Carole L Yauk; Francesco Marchetti
Journal:  Environ Mol Mutagen       Date:  2018-12-21       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.